• Optimizing Assays with (S)-1-(3-fluoro-4-(trifluoromethoxy)p

  2026-07-17

  This article explores scenario-driven best practices for using (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (SKU A8959) in cell viability and enzyme inhibition workflows. Drawing on published evidence and validated product attributes, it addresses reproducibility, protocol optimization, and supplier reliability, empowering researchers to achieve robust and interpretable data.

• Eltanexor (KPT-8602): Advancing XPO1 Inhibition for Cancer T

  2026-07-17

  This article explores the mechanistic, experimental, and translational dimensions of Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, for cancer research. We synthesize recent insights into its unique mode of action, discuss its competitive profile, and provide practical guidance for translational scientists aiming to leverage Eltanexor in disease models, with an outlook on the evolving landscape of nuclear export-targeted therapeutics.

• Eltanexor (KPT-8602): Optimizing XPO1 Inhibition in Cancer R

  2026-07-16

  Eltanexor (KPT-8602) is redefining cancer research by selectively inhibiting XPO1-mediated nuclear export with exceptional potency and tolerability. This guide provides actionable protocols and troubleshooting tips for leveraging Eltanexor in translational and preclinical oncology workflows, grounded in the latest mechanistic and experimental breakthroughs.

• SepM Mutations Enhance S. mutans Inhibition of S. gordonii

  2026-07-16

  Liu et al. (2024) reveal that specific SepM mutations in Streptococcus mutans clinical isolates increase the bacterium's ability to inhibit S. gordonii, a key player in oral biofilm ecology. Their findings clarify the molecular interplay between cariogenic and non-cariogenic oral bacteria and highlight the functional consequences of SepM genetic variation.

• Coumestrol: A Phytoestrogen Estrogen Receptor Antagonist in

  2026-07-15

  Coumestrol stands out as a rigorously validated phytoestrogen estrogen receptor antagonist, enabling precision induction of ferroptosis in rheumatoid arthritis fibroblast models. By bridging nuclear receptor modulation with actionable cell-based workflows, researchers can dissect inflammatory circuits and optimize SERM-based screening with confidence.

• Vaccinia Virus F1L Protein Blocks ZAKα-Driven NLRP1 Inflamma

  2026-07-15

  This study reveals that the vaccinia virus protein F1L specifically inhibits the ZAKα-dependent activation of the NLRP1 inflammasome, thereby subverting key innate immune defense mechanisms. These findings clarify how viral factors can bypass host immune barriers and offer new perspectives for research into inflammasome modulation.

• Ceruletide (Caerulein): Precision Tool for Pancreatic Resear

  2026-07-14

  Ceruletide, also known as Caerulein, is a synthetic decapeptide analog of cholecystokinin used for standardized modeling in pancreatic function research. Its high purity and reproducible CCK receptor agonism make it a cornerstone in gastrointestinal physiology studies and digestive disorder research.

• Eltanexor (KPT-8602): Advanced Protocols in Cancer Research

  2026-07-14

  Eltanexor (KPT-8602) delivers targeted XPO1 inhibition with robust efficacy across hematologic and solid tumor models. This guide translates the latest mechanistic insights and reference-backed findings into streamlined workflows, troubleshooting strategies, and advanced experimental applications, empowering researchers to maximize data quality and reproducibility.

• Phagocytic Polyploid Giant Cancer Macrophages: Biomarkers of

  2026-07-13

  The referenced study provides the first comprehensive phenotypic and clinical analysis of circulating phagocytic polyploid giant cancer macrophages (CAMLs/PGCCs) in diverse solid tumors. By correlating these cells with disease progression and highlighting their unique multipotent and proangiogenic features, this work reframes their role from irrelevant byproducts to potential biomarkers and orchestrators of metastatic niches.

• N-MYC/eIF4G1 Axis Regulates Cell Survival in inv(16) AML

  2026-07-13

  Peramangalam et al. (2024) uncover how N-MYC, governed by a novel enhancer, drives survival of inv(16) acute myeloid leukemia (AML) cells via upregulation of eIF4G1. Their findings provide a mechanistic basis for targeting the CBFβ-SMMHC/N-MYC/eIF4G1 pathway in AML research and highlight the value of selective chemical probes for dissecting leukemogenic circuits.

• Lenalidomide (CC-5013): Mechanisms & Protocols for Myeloma R

  2026-07-12

  Lenalidomide (CC-5013) is a potent immunomodulatory and antineoplastic agent that acts via immune activation, angiogenesis inhibition, and direct tumor suppression. As a mainstay in multiple myeloma research, it demonstrates synergy with epigenetic interventions and robust, literature-backed efficacy benchmarks.

• Foretinib (GSK1363089): Dissecting Drug Response Precision i

  2026-07-10

  Explore how Foretinib (GSK1363089) enables precise, multi-parametric evaluation of tumor cell growth inhibition and cell death in advanced cancer models. This article reveals unique insights into optimizing assay design and data interpretation for translational oncology.

• N-MYC/eIF4G1 Axis Controls Survival in inv(16) AML via CBFβ-

  2026-07-09

  Peramangalam et al. elucidate a novel survival mechanism in inv(16) acute myeloid leukemia (AML), showing that N-MYC regulates cell viability via the translation factor eIF4G1. The study demonstrates that targeting the CBFβ-SMMHC fusion protein disrupts this N-MYC/eIF4G1 axis, offering both mechanistic insights and new avenues for therapeutic intervention in AML research.

• DGLA-Induced Ferroptosis via ACSL4 in Acute Myeloid Leukemia

  2026-07-09

  This study demonstrates that exogenous dihomo-γ-linolenic acid (DGLA) induces ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. The findings advance understanding of lipid-driven cell death as a therapeutic avenue for chemoresistant AML.

• Eltanexor (KPT-8602): Data-Driven Solutions for Cancer Assay

  2026-07-08

  This article delivers practical guidance for using Eltanexor (KPT-8602), SKU B8335, in cell viability and cytotoxicity assays. Scenario-based Q&A blocks reveal how this second-generation XPO1 inhibitor addresses key laboratory challenges with reproducible, evidence-backed performance. Researchers gain actionable protocols and critical insights for integrating Eltanexor into acute myeloid leukemia, chronic lymphocytic leukemia, and colorectal cancer models.

15766 records 1/1052 page Next 12345 下5页 Last page